InterCure Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alexander Rabinovitch
- Full Time Employees
- 285
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 85 Medinat ha-Yehudim Street Herzliya TA Israel 4676670
- IPO Date
- May 24, 2006
- Website
- intercure.co
- Similar Companies
- Business
- InterCure Ltd. engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use, operating primarily through its wholly owned subsidiary Canndoc, Israel's largest licensed cannabis producer. The company’s core product offerings include dried cannabis inflorescences, cannabis oil extracts, and a diversified portfolio of over 80 GMP-certified SKUs encompassing branded products such as Cookies, Binske, and Organigram developed for the medical cannabis market. InterCure also operates a medical cannabis pharmacy chain with 24 active locations in Israel and extends its operations internationally in Germany, the UK, and Australia, targeting patients and healthcare providers in regulated medical cannabis markets. Founded in 1994 and headquartered in Herzliya, Israel, the company leverages a vertically integrated "seed-to-sale" business model that includes cultivation, manufacturing, distribution, and retail. In the past two years, InterCure has implemented significant strategic and operational initiatives. Most notably, the company entered a strategic partnership and collaboration agreement with Cookies™ to cultivate, manufacture, import, and distribute its licensed cannabis genetics and branded products, expanding their footprint notably into the German and UK markets with plans to launch Cookies Corners licensed pharmacies and differentiated online retail platforms in 2024. InterCure is executing a recovery and expansion plan following significant operational disruptions in 2023 due to geopolitical events affecting its Nir Oz facility, with compensation advances received from Israeli authorities and resumption of production at full capacity. The company recently signed a share purchase agreement to acquire ISHI, a U.S.-based cannabis genetics and supply company, to expand its product portfolio and presence in the American market, with the acquisition expected to close in Q1 2026 pending regulatory approval. InterCure also maintains a strong financial position highlighted by NIS 239 million revenue and adjusted EBITDA of NIS 24 million in 2024, signaling solid profitability and growth prospects fueled by product launches, market expansion, and enhanced R&D efforts under leadership focused on pharmaceutical-grade cannabis science. Overall, InterCure operates primarily in the medical cannabis sector and the biomedicine field, with a broad geographical presence spanning Israel, Europe, Australia, and North America through subsidiaries and strategic partnerships. The company continues to advance cannabis science through its R&D pipeline and maintains leadership as a vertically integrated cannabis company outside North America, emphasizing quality standards and global market growth. Its latest strategic emphasis on international partnerships, product innovation, and facility restoration positions InterCure as a key player in the expanding legal medical cannabis industry globally.
Company News
Comparing Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR)
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
InterCure (NASDAQ:INCR) Shares Down 6.6% – Should You Sell?
Head to Head Comparison: InterCure (NASDAQ:INCR) and Jushi (OTCMKTS:JUSHF)
InterCure (NASDAQ:INCR) Shares Up 0.7% – Time to Buy?
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025